Which adverse effect is commonly associated with Bleomycin and Busulfan?

Bleomycin is well-known for its association with pulmonary fibrosis, a serious condition characterized by scarring and inflammation of the lung tissue, which can lead to respiratory difficulties. This adverse effect arises from the unique mechanism of action of Bleomycin, which involves the generation of free radicals that damage lung cells. As a patient progresses through treatment, they may experience symptoms such as cough, dyspnea, and decreased exercise tolerance, indicating potential pulmonary injury.

Busulfan can also contribute to pulmonary fibrosis, particularly when used in higher doses or for extended periods in cancer treatments. It can cause a range of toxicities, but pulmonary toxicity is a significant concern, making it prudent for healthcare professionals to monitor lung function in patients receiving therapy with either drug.

The connection between these two drugs with the risk of pulmonary fibrosis underscores the importance of vigilant monitoring for respiratory symptoms in patients undergoing treatment with Bleomycin and Busulfan. This awareness helps in timely identification and management of potential complications associated with their use.